Statin-Induced Vascular Calcification Mitigation via Ascorbate

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Statin medications, commonly used to treat cardiovascular disease, induce vascular calcification, a risk factor for heart disease, and their side effects include muscle pain, increased diabetes risk, and abnormal liver enzyme levels, with conflicting evidence on their effects on arterial calcification and cardiovascular events.

Innovation Solution

A pharmaceutical composition combining statins with a mixture of vitamins (Vitamin C, Vitamin E, Vitamin B complex, Folic acid, Biotin, L-carnitine, and Betaine) and ascorbate, administered concomitantly to patients, which reduces vascular calcification by inhibiting osteoblastic differentiation and calcium deposition in vascular smooth muscle cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If statins are administered to treat cardiovascular disease, then cholesterol levels are reduced and cardiovascular risk is lowered, but vascular calcification is induced which increases heart disease risk

Engineering Contradiction:

Improvecardiovascular disease treatment effectivenessVSAvoidvascular calcification

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies this principle by using L-ascorbic acid to convert the harmful effect of statin-induced vascular calcification into a beneficial outcome. The ascorbate prevents calcium deposition in vascular smooth muscle cells, thereby transforming the harmful calcification process into a protective effect that maintains vascular health while allowing statin therapy to continue

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

L-ascorbic acid acts as an intermediary substance between statins and vascular smooth muscle cells. It mediates the interaction by preventing the direct harmful effect of statins (calcium deposition) while allowing the beneficial lipid-lowering effects to persist. The ascorbate binds to and stabilizes vitamin K2, creating a protective complex that prevents calcification

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If statins are used to lower cholesterol, then cardiovascular events are reduced, but arterial calcification increases which creates conflicting prognostic signals

Engineering Contradiction:

Improvecardiovascular event reductionVSAvoidarterial calcification marker accuracy

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent converts the harmful marker effect (increased arterial calcification) into a beneficial outcome by using L-ascorbic acid to prevent calcium deposition. This allows the calcification marker to remain accurate while the actual calcification process is prevented, resolving the conflicting prognostic signals

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Object-affected harmful factors

If a mixture of vitamins and ascorbate is combined with statins, then vascular calcification is reduced, but the pharmaceutical composition complexity increases

Engineering Contradiction:

Improvevascular calcification reductionVSAvoidpharmaceutical composition

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent merges multiple protective substances (L-ascorbic acid, vitamin K2, and other vitamins) into a single pharmaceutical composition that can be administered with statins. This combining approach consolidates multiple protective functions into one formulation, reducing the need for multiple separate supplements while maintaining comprehensive protection against calcification

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively mitigates statin-induced vascular calcification, stabilizes vascular walls, and reduces the risk of cardiovascular disease by inhibiting calcification processes, thereby addressing the adverse effects of statin treatment on vascular health.

Implementation Method 1

L-ascorbic acid or ascorbate in a dosage form that allows for administering to a patient. L-ascorbic acid or ascorbate for use in treating or preventing the vascular calcification induced in patients by administration of statins

Methodology Applied

Scientific EffectOsteoblastic differentiation inhibition:

Implementation Method 2

A vascular calcification reducing pharmaceutical composition mixture 1 containing a Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine with statin

Methodology Applied

Scientific EffectCalcium deposition inhibition:

Implementation Method 3

Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine

Methodology Applied

Scientific EffectAntioxidant activity: Oxidation

Data Source

PatentUS10736872B1Pharmaceutical mixture to treat statin induced vascular calcification

Publication Date: 2020.08.11 RATH MATTHIAS W

AI summary

A pharmaceutical composition in a physiological dose for a mammal is used for reducing vascular calcification caused due to statin consumption. The composition contains mixture 1 and statin. The mixture 1 contains combination of the Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine. The mixture 1 can be used as a stand-alone product with or without statin.